8 cannabis articles reviewed and scored below the CED clinical relevance threshold in the February 28, 2026 feed update. Organized by topic with summaries and source links.
Expert breaks down hidden dangers of doctors prescribing medical marijuana – UNILAD
WHY IT MATTERS: Patients using medical cannabis should know that a formal diagnosis or physician recommendation does not eliminate the risk of developing Cannabis Use Disorder, and open communication with your prescribing doctor about frequency and dosage is essential for long-term safety. CLINICAL OVERVIEW: Cannabis Use Disorder is a clinically recognized condition characterized by continued use despite negative consequences, with estimated prevalence rates ranging from roughly 9% of all users to as high as 33% among daily users. The medicalization of cannabis has created a complex dynamic where legitimate therapeutic access may, in some patients, lower the perceived risk of the substance and contribute to problematic use patterns.
Teen Cannabis Use May Double Your Risk of Psychosis and Bipolar
WHY IT MATTERS: Parents, pediatricians, and young people themselves need to understand that the risk calculus for cannabis is not the same at 15 as it is at 35, and that psychosis and bipolar disorder are not rare or abstract outcomes but life-altering diagnoses with serious long-term consequences. CLINICAL OVERVIEW: The relationship between adolescent cannabis use and psychiatric outcomes has been a subject of serious scientific inquiry for decades, with converging evidence suggesting that exposure during neurodevelopmental windows carries meaningfully different risks than adult-onset use. The adolescent brain, particularly the prefrontal cortex and limbic system, undergoes significant synaptic pruning and maturation through the mid-twenties, and the endocannabinoid system plays a direct regulatory role in that process.
Daily Digest: Last 24 Hours: CHS Awareness, Prenatal Risk, and the Endocannabinoid System’s Expanding Reach — February 28, 2026
✦ New CED Clinical Relevance#72Notable Clinical InterestEmerging findings or policy developments worth monitoring closely. SafetyResearchMental HealthPediatrics Why This MattersCannabinoid hyperemesis syndrome and prenatal cannabis exposure represent clinically significant adverse outcomes that warrant...
Aelis Farma’s AEF0117 THC Interaction Trial Withdrawn: What Investors Should Know
WHY IT MATTERS: Patients and clinicians hoping for a targeted pharmacological tool to manage THC overconsumption or cannabis use disorder may face longer timelines before any such option becomes available. CLINICAL OVERVIEW: AEF0117 is a first-in-class CB1 receptor signaling inhibitor developed by Aelis Farma, designed to selectively block certain downstream effects of THC without fully antagonizing the receptor, representing a novel pharmacological approach to cannabis use disorder and THC-related adverse effects. The withdrawal of a THC interaction trial is a meaningful setback because interaction studies are critical for characterizing how AEF0117 behaves in the presence of active THC, which is the precise clinical scenario the drug is meant to address.
DOSE) (OTCQB: RDTCF) Advances QuickStrip™ Research Backed by NFL … – StreetInsider
WHY IT MATTERS: If thin-film CBD delivery is confirmed to offer superior and more consistent bioavailability compared to traditional oral products, patients may need to recalibrate their doses when switching formats to avoid unintended underdosing or overdosing. CLINICAL OVERVIEW: Sublingual and buccal thin-film delivery systems represent a meaningful departure from conventional oral cannabinoid formats because they bypass first-pass hepatic metabolism, potentially improving both the speed of onset and the consistency of systemic absorption. CBD delivered through mucoadhesive strip technology may achieve higher bioavailability compared to standard oil-based or capsule formulations, which are notoriously variable due to differences in fed versus fasted states and individual digestive physiology.
First-of-its-kind long-term study at Virginia Tech shares how cannabis use can affect driving
WHY IT MATTERS: Patients who use cannabis medicinally need to understand that subjective feelings of being “fine to drive” can diverge significantly from actual measured driving performance, particularly in the hours following consumption. CLINICAL OVERVIEW: The relationship between cannabis consumption and driving performance is genuinely complex, because THC impairment does not follow the same linear dose-response curve that alcohol does, and standard roadside testing fails to capture the nuanced ways cannabis affects reaction time, lane tracking, and divided attention. Tolerance, consumption method, cannabinoid ratios, and individual pharmacokinetics all influence how significantly any given person is impaired behind the wheel.
Cannabis use, anxiety and depression are all on the rise in Canada: study – CTV News
WHY IT MATTERS: Patients using cannabis to manage anxiety or depression should be aware that without proper medical guidance on strain selection, THC-to-CBD ratios, and dosing, cannabis may be worsening the very symptoms they are trying to treat. CLINICAL OVERVIEW: Research from Canada is highlighting a parallel rise in cannabis use alongside increasing rates of anxiety and depression, raising important questions about the direction of causality and the role cannabis may be playing in mental health outcomes. The relationship between cannabis and mood disorders is complex, as individuals may be turning to cannabis to self-manage psychological distress while the substance itself, particularly high-THC products, can worsen anxiety and depressive symptoms over time.
Marijuana Use & Dangers for Adolescents & Young Adults
WHY IT MATTERS: Parents, school counselors, and young people themselves should understand that regular cannabis use during adolescence is not a benign habit but a potential accelerant for mental health problems that may require professional intervention. CLINICAL OVERVIEW: Adolescents and young adults represent a particularly vulnerable population when it comes to cannabis use, largely because the brain continues developing well into the mid-twenties, making it highly susceptible to the neurological effects of THC during this window. When cannabis use disorder co-occurs with underlying mental health conditions such as anxiety, depression, or early psychotic spectrum disorders, the clinical picture becomes substantially more complex and harder to treat.
Screaming, vomiting, and daily weed: The rise of ‘scromiting’ among chronic cannabis users
WHY IT MATTERS: If you use cannabis daily and experience recurring episodes of severe vomiting that hot showers seem to relieve, you should discuss cannabinoid hyperemesis syndrome with your physician before your next emergency room visit. CLINICAL OVERVIEW: Cannabinoid hyperemesis syndrome is a paradoxical condition in which heavy, long-term cannabis use causes cyclical episodes of severe nausea, vomiting, and abdominal pain, often relieved temporarily by hot showers or baths. The syndrome is thought to involve dysregulation of cannabinoid receptors in the gut and hypothalamus, particularly with chronic high-potency THC exposure, though the precise mechanism remains under active investigation.